{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T19:28:42Z","timestamp":1680031722063},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00115-019-0724-4","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T09:40:59Z","timestamp":1559641259000},"page":"781-786","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antisense-Therapie neurologischer Erkrankungen"],"prefix":"10.1007","volume":"90","author":[{"given":"Stefan\u2011M.","family":"Pulst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"issue":"2","key":"724_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","volume":"26","author":"D Alarc\u00f3n-Ar\u00eds","year":"2018","unstructured":"Alarc\u00f3n-Ar\u00eds D, Recasens A, Galofre M et al (2018) Selective alpha-Synuclein knockdown in Monoamine neurons by Intranasal Oligonucleotide delivery: potential therapy for parkinson\u2019s disease. Mol Ther 26(2):550\u2013567","journal-title":"Mol Ther"},{"issue":"7650","key":"724_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nature22038","volume":"544","author":"LA Becker","year":"2017","unstructured":"Becker LA, Huang B, Bieri G et al (2017) Therapeutic reduction of ataxin-2 extend lifespan and reduces pathology inTD-43 mice. Nature 544(7650):367\u2013371","journal-title":"Nature"},{"key":"724_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennet","year":"2019","unstructured":"Bennet CF (2019) Therapeutic Antisense Oligonucleotides are coming of age. Annu Rev Med 70:307\u2013321","journal-title":"Annu Rev Med"},{"issue":"1","key":"724_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary Transthyretin Amyloidosis. N\u00a0Engl J Med 379(1):22\u201331","journal-title":"N Engl J Med"},{"issue":"6","key":"724_CR5","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.ymthe.2018.02.029","volume":"26","author":"JL Chang","year":"2018","unstructured":"Chang JL, Hinrich AJ, Roman B et al (2018) Targeting Amyloid-beta precursor protein, APP, splicing with Antisense Oligonucleotides reduces toxic Amyloid-beta production. Mol Ther 26(6):1539\u20131551","journal-title":"Mol Ther"},{"issue":"3","key":"724_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"ST Crooke","year":"2017","unstructured":"Crooke ST, Wang S, Vickers TA et\u00a0al (2017) Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 35(3):230\u2013237","journal-title":"Nat Biotechnol"},{"issue":"1","key":"724_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1089\/nat.2018.0753","volume":"29","author":"ST Crooke","year":"2019","unstructured":"Crooke ST, Baker BF, Xia S et\u00a0al (2019) Integrated assessment of the clinical performance of GalNac3-conjugated 2\u2032-O-Methoxyethyl chimeric Antisense Oligonucleotides: I. Human volunteer experience. Nucleic Acid Ther 29(1):16\u201332","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"724_CR8","doi-asserted-by":"publisher","first-page":"e1005182","DOI":"10.1371\/journal.pgen.1005182","volume":"11","author":"W Dansithong","year":"2015","unstructured":"Dansithong W, Paul S, Figueroa KP et al (2015) Ataxin-2 regulates RGS8 translation in a\u00a0new BAC-SCA2 transgenic mouse model. Plos Genet 11(4):e1005182","journal-title":"Plos Genet"},{"issue":"374","key":"724_CR9","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM et\u00a0al (2017) Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 9(374):eaag481","journal-title":"Sci Transl Med"},{"issue":"16 Suppl","key":"724_CR10","first-page":"46.003","volume":"88","author":"DC De Vivo","year":"2017","unstructured":"De Vivo DC, Hwu W\u2011L, Reyna SP et al (2017) Interim efficacy and safety results from the phase 2 Nurture study evaluating Nusinersen in presympotmatic infants with spinal muscular atrophy. Baillieres Clin Neurol 88(16 Suppl):46.003","journal-title":"Baillieres Clin Neurol"},{"issue":"18","key":"724_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N\u00a0Engl J Med 377(18):1723\u20131732","journal-title":"N Engl J Med"},{"issue":"2","key":"724_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/hmg\/dds427","volume":"22","author":"ST Hansen","year":"2013","unstructured":"Hansen ST, Meera P, Otis TS, Pulst SM (2013) Changes in Purkinje cell firing and gene expression precede behavioral pathology in a\u00a0mouse model of SCA2. Hum Mol Genet 22(2):271\u2013283","journal-title":"Hum Mol Genet"},{"issue":"4","key":"724_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.15252\/emmm.201505846","volume":"8","author":"AJ Hinrich","year":"2016","unstructured":"Hinrich AJ, Jodelka FM, Chang JL et\u00a0al (2016) Therapeutic correction of ApoER2 splicing in Alzheimer\u2019s disease mice using antisense oligonucleotides. Embo Mol Med 8(4):328\u2013345","journal-title":"Embo Mol Med"},{"issue":"9","key":"724_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Butler DCD, Svrzikapa N et\u00a0al (2017) Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol 35(9):845\u2013851","journal-title":"Nat Biotechnol"},{"issue":"30","key":"724_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","volume":"90","author":"J Jiang","year":"2016","unstructured":"Jiang J, Zhu Q, Gendron TF et al (2016) Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by Antisense Oligonucleotides targeting GGGGCC-containing RNas. Neuron 90(30):535\u2013550","journal-title":"Neuron"},{"key":"724_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/978-1-4939-7825-0_23","volume":"1780","author":"RM Lane","year":"2018","unstructured":"Lane RM, Smith A, Baumann T et\u00a0al (2018) Translating Antisense technology into a\u00a0treatment for Huntington\u2019s disease. Methods Mol Biol 1780:497\u2013523","journal-title":"Methods Mol Biol"},{"key":"724_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"724_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jama.280.10.871-JMN0909-6-1","volume":"280","author":"C Marwick","year":"1998","unstructured":"Marwick C (1998) First \u201cantisense\u201d drug will treat CMV retinitis. JAMA 280(10):871","journal-title":"JAMA"},{"issue":"8","key":"724_CR19","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A, Cole T, Wegener AJ et\u00a0al (2018) Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J\u00a0Clin Invest 128(8):3558\u20133567","journal-title":"J Clin Invest"},{"issue":"1","key":"724_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ana.25264","volume":"84","author":"HS McLoughlin","year":"2018","unstructured":"McLoughlin HS, Moore LR, Chopra R et\u00a0al (2018) Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Ann Neurol 84(1):64\u201377","journal-title":"Ann Neurol"},{"issue":"7","key":"724_CR21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N\u00a0Engl J Med 378(7):625\u2013635","journal-title":"N Engl J Med"},{"issue":"20","key":"724_CR22","first-page":"923","volume":"91","author":"D Michelson","year":"2018","unstructured":"Michelson D, Ciafaloni E, Ashwal S et\u00a0al (2018) Evidence in focus: Nusinersen use in spinal muscular atrophy. Baillieres Clin Neurol 91(20):923\u2013933","journal-title":"Baillieres Clin Neurol"},{"issue":"12","key":"724_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jamaneurol.2014.2082","volume":"71","author":"AG Neuenschwander","year":"2014","unstructured":"Neuenschwander AG, Thai KK, Figueroa KP et al (2014) Amyotrophic lateral sclerosis risk for spinocerebellar ataxia type 2 ATXN2 CAG repeat alleles: a\u00a0meta-analysis. Jama Neurol 71(12):1529\u20131534","journal-title":"Jama Neurol"},{"issue":"465","key":"724_CR24","doi-asserted-by":"publisher","first-page":"eaap8677","DOI":"10.1126\/scitranslmed.aap8677","volume":"10","author":"C Niu","year":"2018","unstructured":"Niu C, Prakash TP, Kim A et al (2018) Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a\u00a0mouse model of spinocerebellar ataxia type 7. Sci Transl Med 10(465):eaap8677","journal-title":"Sci Transl Med"},{"issue":"5","key":"724_CR25","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","volume":"61","author":"D Oldenburg","year":"2019","unstructured":"Oldenburg D, Guberina N, Stolte B et al (2019) Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy. Neuroradiology 61(5):565\u2013574. \n                    https:\/\/doi.org\/10.1007\/s00234-019-02189-x","journal-title":"Neuroradiology"},{"issue":"7650","key":"724_CR26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature22044","volume":"554","author":"DR Scoles","year":"2017","unstructured":"Scoles DR, Meera P, Schneider MD et\u00a0al (2017) Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature 554(7650):362\u2013366","journal-title":"Nature"},{"key":"724_CR27","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","volume":"5","author":"DR Scoles","year":"2019","unstructured":"Scoles DR, Minikel EV, Pulst SM (2019) Antisense oligonucleotides: a primer. Neurol Genet 5:e323","journal-title":"Neurol Genet"},{"key":"724_CR28","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","volume":"8","author":"LJA Toonen","year":"2017","unstructured":"Toonen LJA, Rigo F, van Attikum H et al (2017) Antisense Oligonucleotide-mediated removal of the Polyglutamine repeat in spinocerebellar ataxia type 3 mice. Mol Ther Nucleic Acids 8:232\u2013242","journal-title":"Mol Ther Nucleic Acids"},{"key":"724_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","volume":"8","author":"HT Zhao","year":"2017","unstructured":"Zhao HT, John N, Delic V et al (2017) LRRK2 Antisense Oligonucleotides ameliorate alpha-Synuclein inclusion formation in a\u00a0parkinson\u2019s disease mouse model. Mol Ther Nucleic Acids 8:508\u2013519","journal-title":"Mol Ther Nucleic Acids"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-019-0724-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-019-0724-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T23:14:59Z","timestamp":1591139699000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-019-0724-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s00115-019-0724-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]},"assertion":[{"value":"4 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u2011M.\u00a0Pulst erh\u00e4lt Lizenzgeb\u00fchren von der University of Utah, Cedars-Sinai Medical Center, und von der American Academy of Neurology. Er ist Mitbesitzer eines Patentes f\u00fcr ATXN2 ASOs mit Ionis Pharmaceuticals. Er ist Mitbegr\u00fcnder von Progenitor Lifesciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}